Why McKesson (MCK) Dipped More Than Broader Market Today

McKesson (MCK) stock closed down 1.53% at $724.11, underperforming the S&P 500's minor daily loss, though it has gained 3.83% over the past month. The prescription drug distributor is slated to report earnings on August 6, 2025, with consensus estimates projecting $8.25 EPS (+4.7% YoY) and $96.08 billion revenue (+21.18% YoY) for the quarter, alongside robust full-year growth forecasts. Currently holding a Zacks Rank of #2 (Buy) and benefiting from recent upward EPS estimate revisions, MCK trades at a Forward P/E of 19.74, a slight premium to its industry, but a favorable PEG ratio of 1.47, suggesting a positive outlook despite the recent dip.

Analysis

Despite a recent single-day decline of 1.53% to $724.11, underperforming the broader market, McKesson (MCK) has demonstrated solid performance over the past month with a 3.83% gain, outpacing the Medical sector's 1.3% loss. The fundamental outlook for the company appears robust, supported by strong forward-looking consensus estimates. For its upcoming earnings report on August 6, 2025, analysts project significant year-over-year revenue growth of 21.18% to $96.08 billion, alongside a 4.7% increase in EPS to $8.25. The full-year forecast is also strong, with expectations for double-digit growth in both revenue (+13.05%) and EPS (+12.71%). This positive sentiment is reinforced by a recent upward revision in consensus EPS estimates and a Zacks Rank of #2 (Buy). From a valuation standpoint, MCK trades at a forward P/E of 19.74, a slight premium to its industry average of 18.21. However, its PEG ratio of 1.47 is more favorable than the industry's 1.67, suggesting its price may be justified by its expected earnings growth, further supported by its position in a highly-ranked industry.

Key Decisions for Investors

• Consider the recent single-day price dip as a potential entry point, as the broader fundamental picture remains strong with double-digit full-year growth projections and positive analyst estimate revisions.
• Evaluate the stock's valuation, noting that its premium forward P/E is partially offset by a more favorable PEG ratio relative to its industry, suggesting its growth prospects are a key justification for the price.
• Closely monitor the upcoming earnings report on August 6, 2025, paying particular attention to whether the company meets the high consensus revenue growth expectation of 21.18% YoY, which is a key component of the current bullish thesis.
• The combination of a #2 (Buy) Zacks Rank and the company's position in a top-performing industry (top 12%) provides a strong quantitative signal that may support maintaining or initiating a bullish position.